Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms

NCT06211764 2026-06-05

SunRISe-5

Phase 3 Active not recruiting

272 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-06-05

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-06-05

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07309445 2026-06-05

Nova-sTAR

Recruiting

150 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07625527 2026-06-04

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

Phase 2 Not yet recruiting

120 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT04375813 2026-06-03

eRapa

Phase 2 Active not recruiting

166 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07000084 2026-06-02

GAIN-BCG

Phase 3 Recruiting

330 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Phase 3 Not yet recruiting

236 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07144319 2026-05-29

ENAiBLE

Recruiting

500 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06833073 2026-05-28

INTerpath-011

Phase 2 Recruiting

308 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06972615 2026-05-28

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Phase 2 Recruiting

37 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05710848 2026-05-27

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Phase 1/2 Recruiting

75 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05943106 2026-05-26

PATAPSCO

Phase 3 Active not recruiting

100 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT02106572 2026-05-22

TIM

Phase 3 Terminated

174 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07602010 2026-05-22

Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging

Recruiting

150 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06995677 2026-05-20

SURF302

Phase 2 Recruiting

90 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07551544 2026-05-19

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

Phase 3 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05951179 2026-05-18

ADVANCED-2

Phase 2 Recruiting

131 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Clinical Trials

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

SunRISe-5

MoonRISe-1

MoonRISe-3

Nova-sTAR

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

eRapa

GAIN-BCG

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

ENAiBLE

INTerpath-011

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

PATAPSCO

TIM

Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging

SURF302

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

ADVANCED-2